Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 13/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009584 | 0.94 | IGF1R (0.33) | IGF1RPTGS1PTGS2 | |
| SCHEMBL1009867 | 0.93 | IGF1R (0.34) | IGF1RPTGS1PTGS2 | |
| SCHEMBL1009798 | 0.92 | IGF1R (0.38) | IGF1RPTGS1PTGS2 | |
| SCHEMBL1008714 | 0.91 | PTGS2 (0.35) | PTGS1PTGS2 | |
| SCHEMBL1008492 | 0.91 | IGF1R (0.32) | IGF1R | |
| SCHEMBL1010473 | 0.89 | PTGS1 (0.42) | IGF1RPTGS1PTGS2 | |
| SCHEMBL1008999 | 0.88 | IGF1R (0.32) | IGF1R | |
| SCHEMBL1009682 | 0.86 | PTGS1 (0.40) | IGF1RPTGS1PTGS2CA1CA2 | |
| SCHEMBL1009301 | 0.86 | PTGS1 (0.40) | IGF1RPTGS1PTGS2 | |
| SCHEMBL1008459 | 0.86 | PTGS1 (0.42) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915258-B2 | Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one derivatives, preparation thereof and therapeutic use of the same | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | claimed |
| EP-2094706-B1 | SUBSTITUTED 2,5-DFFLYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND USE OF SAME AS CANNABINOID CB1 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2011-01-05 | — | — | EP | claimed |
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | claimed |
| EP-2094706-A2 | SUBSTITUTED 2,5-DFFLYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND USE OF SAME AS CANNABINOID CB1 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2009-09-02 | — | — | EP | claimed |
| WO-2008068424-A2 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND USE OF SAME AS CANNABINOID CB1 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2008-06-12 | — | — | WO | claimed |
| EP-2094706-B1 | SUBSTITUTED 2,5-DFFLYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND USE OF SAME AS CANNABINOID CB1 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | DHFR, DPYD, QDPR | IGF1R 2597/4885PTGS1 688/4885PTGS2 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.